Cargando…
Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective
Prostate cancer is one of the most often diagnosed malignancies in males and its prevalence is rising in both developed and developing countries. Androgen deprivation therapy has been used as a standard treatment approach for advanced prostate cancer for more than 80 years. The primary aim of androg...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tech Science Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208071/ https://www.ncbi.nlm.nih.gov/pubmed/37305018 http://dx.doi.org/10.32604/or.2022.026074 |
_version_ | 1785046594097250304 |
---|---|
author | VARISLI, LOKMAN TOLAN, VEYSEL CEN, JIYAN H. VLAHOPOULOS, SPIROS CEN, OSMAN |
author_facet | VARISLI, LOKMAN TOLAN, VEYSEL CEN, JIYAN H. VLAHOPOULOS, SPIROS CEN, OSMAN |
author_sort | VARISLI, LOKMAN |
collection | PubMed |
description | Prostate cancer is one of the most often diagnosed malignancies in males and its prevalence is rising in both developed and developing countries. Androgen deprivation therapy has been used as a standard treatment approach for advanced prostate cancer for more than 80 years. The primary aim of androgen deprivation therapy is to decrease circulatory androgen and block androgen signaling. Although a partly remediation is accomplished at the beginning of treatment, some cell populations become refractory to androgen deprivation therapy and continue to metastasize. Recent evidences suggest that androgen deprivation therapy may cause cadherin switching, from E-cadherin to N-cadherin, which is the hallmark of epithelial-mesenchymal transition. Diverse direct and indirect mechanisms are involved in this switching and consequently, the cadherin pool changes from E-cadherin to N-cadherin in the epithelial cells. Since E-cadherin represses invasive and migrative behaviors of the tumor cells, the loss of E-cadherin disrupts epithelial tissue structure leading to the release of tumor cells into surrounding tissues and circulation. In this study, we review the androgen deprivation therapy-dependent cadherin switching in advanced prostate cancer with emphasis on its molecular basis especially the transcriptional factors regulated through TFG-β pathway. |
format | Online Article Text |
id | pubmed-10208071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Tech Science Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102080712023-06-10 Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective VARISLI, LOKMAN TOLAN, VEYSEL CEN, JIYAN H. VLAHOPOULOS, SPIROS CEN, OSMAN Oncol Res Review Prostate cancer is one of the most often diagnosed malignancies in males and its prevalence is rising in both developed and developing countries. Androgen deprivation therapy has been used as a standard treatment approach for advanced prostate cancer for more than 80 years. The primary aim of androgen deprivation therapy is to decrease circulatory androgen and block androgen signaling. Although a partly remediation is accomplished at the beginning of treatment, some cell populations become refractory to androgen deprivation therapy and continue to metastasize. Recent evidences suggest that androgen deprivation therapy may cause cadherin switching, from E-cadherin to N-cadherin, which is the hallmark of epithelial-mesenchymal transition. Diverse direct and indirect mechanisms are involved in this switching and consequently, the cadherin pool changes from E-cadherin to N-cadherin in the epithelial cells. Since E-cadherin represses invasive and migrative behaviors of the tumor cells, the loss of E-cadherin disrupts epithelial tissue structure leading to the release of tumor cells into surrounding tissues and circulation. In this study, we review the androgen deprivation therapy-dependent cadherin switching in advanced prostate cancer with emphasis on its molecular basis especially the transcriptional factors regulated through TFG-β pathway. Tech Science Press 2023-01-12 /pmc/articles/PMC10208071/ /pubmed/37305018 http://dx.doi.org/10.32604/or.2022.026074 Text en © 2022 Varisli et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review VARISLI, LOKMAN TOLAN, VEYSEL CEN, JIYAN H. VLAHOPOULOS, SPIROS CEN, OSMAN Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective |
title | Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective |
title_full | Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective |
title_fullStr | Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective |
title_full_unstemmed | Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective |
title_short | Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective |
title_sort | dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: a molecular perspective |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208071/ https://www.ncbi.nlm.nih.gov/pubmed/37305018 http://dx.doi.org/10.32604/or.2022.026074 |
work_keys_str_mv | AT varislilokman dissectingtheeffectsofandrogendeprivationtherapyoncadherinswitchinginadvancedprostatecanceramolecularperspective AT tolanveysel dissectingtheeffectsofandrogendeprivationtherapyoncadherinswitchinginadvancedprostatecanceramolecularperspective AT cenjiyanh dissectingtheeffectsofandrogendeprivationtherapyoncadherinswitchinginadvancedprostatecanceramolecularperspective AT vlahopoulosspiros dissectingtheeffectsofandrogendeprivationtherapyoncadherinswitchinginadvancedprostatecanceramolecularperspective AT cenosman dissectingtheeffectsofandrogendeprivationtherapyoncadherinswitchinginadvancedprostatecanceramolecularperspective |